{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["7(24)"],"submitter":["Altman JK"],"pubmed_abstract":["High-dose cytarabine is associated with gastrointestinal and cerebellar toxicity, precluding its use for older or unfit patients with acute myeloid leukemia (AML). Aspacytarabine, an inactive prodrug of cytarabine, was evaluated as monotherapy in a phase 2b study of patients unfit for intensive chemotherapy (NCT03435848). Sixty-five patients with AML were treated with aspacytarabine 4.5 g/m2 per day (equimolar to 3 g/m2 per day cytarabine) for 6 doses per treatment. The median age was 75 years; 60.6% of patients had de novo AML, 28.8% had AML secondary to myelodysplastic syndrome, and 10.6% had therapy-related AML. Overall, 36.9% achieved complete remission (CR) with full count recovery. CR rates in patients with secondary AML, patients with prior treatment with hypomethylating agents, and"],"journal":["Blood advances"],"pagination":["7494-7500"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10758705"],"repository":["biostudies-literature"],"pubmed_title":["Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 study."],"pmcid":["PMC10758705"],"pubmed_authors":["Levi I","Burch M","Zuckerman T","Percival ME","Gengrinovitch S","Luger SM","Ganzel C","Keng M","Abaza Y","Bhatnagar B","Blumberg C","Frankfurt O","Kota V","Altman JK","Emadi A","Wolach O","Gourevitch A","Koprivnikar J","Tessler S","Ben Yakar R","Craig M","Flaishon L","Roboz G","McCloskey J","Rowe JM","Bixby DL"],"additional_accession":[]},"is_claimable":false,"name":"Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 study.","description":"High-dose cytarabine is associated with gastrointestinal and cerebellar toxicity, precluding its use for older or unfit patients with acute myeloid leukemia (AML). Aspacytarabine, an inactive prodrug of cytarabine, was evaluated as monotherapy in a phase 2b study of patients unfit for intensive chemotherapy (NCT03435848). Sixty-five patients with AML were treated with aspacytarabine 4.5 g/m2 per day (equimolar to 3 g/m2 per day cytarabine) for 6 doses per treatment. The median age was 75 years; 60.6% of patients had de novo AML, 28.8% had AML secondary to myelodysplastic syndrome, and 10.6% had therapy-related AML. Overall, 36.9% achieved complete remission (CR) with full count recovery. CR rates in patients with secondary AML, patients with prior treatment with hypomethylating agents, and","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Dec","modification":"2025-05-29T22:24:31.069Z","creation":"2025-05-29T22:24:31.069Z"},"accession":"S-EPMC10758705","cross_references":{"pubmed":["37903324"],"doi":["10.1182/bloodadvances.2023010943"]}}